Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Mechanical Valve Divestiture Is Defining Move For MedicalCV’s New CEO

This article was originally published in The Gray Sheet

  • News

Executive Summary

MedicalCV will conduct an IDE clinical study to investigate its Atrilaze soft tissue ablation system for cardiac arrhythmias, following an initial 510(k) clearance

You may also be interested in...



MedicalCV AtriLaze

Surgical cardiac tissue ablation system will begin U.S. shipping in January; the firm announced 510(k) clearance Dec. 13. MedicalCV plans a trial for an atrial fibrillation claim (1"The Gray Sheet" Nov. 29, 2004, p. 18)...

MedicalCV AtriLaze

Surgical cardiac tissue ablation system will begin U.S. shipping in January; the firm announced 510(k) clearance Dec. 13. MedicalCV plans a trial for an atrial fibrillation claim (1"The Gray Sheet" Nov. 29, 2004, p. 18)...

St. Jude Builds AF Strategy With $273 Mil. Endocardial Solutions Purchase

St. Jude Medical gains ablation catheter navigation technology to augment its atrial fibrillation portfolio under a $273 mil. acquisition of Endocardial Solutions

Table

View full table

Related Content

Medtech Insight
Tags:
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT021239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By